首页>Acta neurologica Scandinavica.>OnabotulinumtoxinA for chronic migraine: Efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
OnabotulinumtoxinA for chronic migraine: Efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
作者单位:Mayo Clinic Arizona, Phoenix, AZ, United States[1]Stanford University, Stanford, CA, United States[2]University of Essen, Essen, Germany[3]Albert Einstein College of Medicine, Bronx, NY, United States[4]Allergan, Inc., Irvine, CA, United States[5]Thomas Jefferson University, Philadelphia, PA, United States[6]